Deep-brain stimulation for Parkinson's disease

New England Journal of Medicine

Volumn 367, Issue 16, 2012, Pages 1529-1538

  Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR;

AGED; AMNESIA; BALANCE DISORDER; BRADYKINESIA; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; BRAIN INFECTION; CASE REPORT; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; DYSPHAGIA; EVIDENCE BASED MEDICINE; GLOBUS PALLIDUS; HUMAN; IMPULSIVENESS; MALE; MENTAL DISEASE; NEUROLOGIC EXAMINATION; NEUROLOGIST; NEUROSURGEON; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RIGIDITY; SENSORIMOTOR NEUROPATHY; SPEECH DISORDER; SUBTHALAMIC NUCLEUS; SUICIDAL IDEATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; WALKING;

EID: 84867615119     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1208070     Document Type: Article

References (61)

1. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol 2000;13:427-30.
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
3. Lang AE, Lozano AM. Parkinson's disease (first of two parts). N Engl J Med 1998;339:1044-53.
4. Baumann CR. Epidemiology, diagnosis and differential diagnosis in Parkinson's disease tremor. Parkinsonism Relat Disord 2012;18:Suppl 1:S90-S92.
5. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-23.
6. Martikainen KK, Luukkaala TH, Marttila RJ. Parkinson's disease and working capacity. Mov Disord 2006;21:2187-91.
7. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson's disease. Mov Disord 1998;13:249-54.
8. Dodel RC, Singer M, Kohne-Volland R, et al. Cost of illness in Parkinson disease: a retrospective 3-month analysis of direct costs. Nervenarzt 1997;68:978-84. (In German.)
9. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003;18:1139-45.
10. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-9.
11. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008;70:1423-30.
12. Willis AW, Schootman M, Evanoff BA, Perlmutter JS, Racette BA. Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology 2011;77:851-7.
13. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81.
14. Delong MR, Georgopoulos AP, Crutcher MD, Mitchell SJ, Richardson RT, Alexander GE. Functional organization of the basal ganglia: contributions of single-cell recording studies. Ciba Found Symp 1984;107:64-82.
15. Wagle Shukla A, Okun MS. Personalized medicine in deep brain stimulation through utilization of neural oscillations. Neurology 2012;78:1900-1.
16. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47: Suppl 1:S2-S9.
17. Okun MS, Fernandez HH, Rodriguez RL, Foote KD. Identifying candidates for deep brain stimulation in Parkinson's disease: the role of the primary care physician. Geriatrics 2007;62:18-24.
18. McIntyre CC, Hahn PJ. Network perspectives on the mechanisms of deep brain stimulation. Neurobiol Dis 2010;38:329-37.
19. Vitek JL. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Disord 2002;17:Suppl 3:S69-S72.
20. Wichmann T, DeLong MR, Guridi J, Obeso JA. Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord 2011;26:1032-41.
21. Tawfik VL, Chang SY, Hitti FL, et al. Deep brain stimulation results in local glutamate and adenosine release: investigation into the role of astrocytes. Neurosurgery 2010;67:367-75.
22. Lee KH, Hitti FL, Chang SY, et al. High frequency stimulation abolishes thalamic network oscillations: an electrophysiological and computational analysis. J Neural Eng 2011;8(4):046001.
23. Lee KH, Chang SY, Roberts DW, Kim U. Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus. J Neurosurg 2004;101:511-7.
24. Vedam-Mai V, van Battum EY, Kamphuis W, et al. Deep brain stimulation and the role of astrocytes. Mol Psychiatry 2012;17:124-31.
25. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908. [Erratum, N Engl J Med 2006;355:1289.]
26. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
27. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-91.
28. Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009;65:586-95.
29. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7.
30. Goetz CG, Stebbins GT, Tilley BC. Calibration of Unified Parkinson's Disease Rating Scale scores to Movement Disorder Society-Unified Parkinson's Disease Rating Scale scores. Mov Disord 2012;27:1239-42.
31. Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 2006;29:322-30.
32. Okun MS, Foote KD. Enough is enough: moving on to deep brain stimulation in patients with fluctuating Parkinson disease. Arch Neurol 2009;66:778-80.
33. Okun MS, Fernandez HH, Pedraza O, et al. Development and initial validation of a screening tool for Parkinson disease surgical candidates. Neurology 2004;63:161-3.
34. Okun MS, Foote KD. Parkinson's disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother 2010;10:1847-57.
35. Okun MS, Foote KD. A mnemonic for Parkinson disease patients considering DBS: a tool to improve perceived outcome of surgery. Neurologist 2004;10:290.
36. Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. Neurologist 2007;13:253-60.
37. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550-6.
38. Hooper AK, Okun MS, Foote KD, et al. Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact Funct Neurosurg 2008;86:147-52.
39. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-71.
40. Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-23.
41. Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005;62:1250-5.
42. Ellis TM, Foote KD, Fernandez HH, et al. Reoperation for suboptimal outcomes after deep brain stimulation surgery. Neurosurgery 2008;63:754-60.
43. Okun MS, Rodriguez RL, Foote KD, et al. A case-based review of trouble-shooting deep brain stimulator issues in movement and neuropsychiatric disorders. Parkinsonism Relat Disord 2008;14:532-8.
44. Voges J, Waerzeggers Y, Maarouf M, et al. Deep-brain stimulation: long-term analysis of complications caused by hardware and surgery - experiences from a single centre. J Neurol Neurosurg Psychiatry 2006;77:868-72.
45. Sillay KA, Larson PS, Starr PA. Deep brain stimulator hardware-related infections: incidence and management in a large series. Neurosurgery 2008;62:360-6.
46. Fenoy AJ, Simpson RK. Management of device-related wound complications in deep-brain stimulation surgery. J Neurosurg 2012;116:1324-32.
47. Zrinzo L, Foltynie T, Limousin P, Hariz MI. Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg 2012;116:84-94.
48. Coley E, Farhadi R, Lewis S, Whittle IR. The incidence of seizures following deep brain stimulating electrode implantation for movement disorders, pain and psychiatric conditions. Br J Neurosurg 2009;23:179-83.
49. Falowski S, Ooi YC, Smith A, Verhargen Metman L, Bakay RA. An evaluation of hardware and surgical complications with deep brain stimulation based on diagnosis and lead location. Stereotact Funct Neurosurg 2012;90:173-80.
50. Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. Mov Disord 2002;17:Suppl 3:S181-S187.
51. Temel Y. Limbic effects of high-frequency stimulation of the subthalamic nucleus. Vitam Horm 2010;82:47-63.
52. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012;7(1):e29768.
53. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a metaanalysis. Lancet Neurol 2006;5:578-88.
54. Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012;11:140-9. [Erratum, Lancet Neurol 2012;11:208.]
55. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-91.
56. Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: thirty-sixmonth outcomes. Neurology 2012;79:55-65.
57. Taba HA, Wu SS, Foote KD, et al. A closer look at unilateral versus bilateral deep brain stimulation: results of the National Institutes of Health COMPARE cohort. J Neurosurg 2010;113:1224-9.
58. Alberts JL, Hass CJ, Vitek JL, Okun MS. Are two leads always better than one: an emerging case for unilateral subthalamic deep brain stimulation in Parkinson's disease. Exp Neurol 2008;214:1-5.
59. Alberts JL, Okun MS, Vitek JL. The persistent effects of unilateral pallidal and subthalamic deep brain stimulation on force control in advanced Parkinson's patients. Parkinsonism Relat Disord 2008;14:481-8.
60. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-95.
61. Moro E, Allert N, Eleopra R, Houeto JL, Phan TM, Stoevelaar H. A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. J Neurol 2009;256:83-8.